newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders

  • IGC Pharma held its Annual Meeting of Stockholders on October 10, 2025, where all proposed items were approved by stockholders of record as of July 28, 2025.
  • The company elected Mr. Ram Mukunda and Mr. James Moran to its board of directors as Class C directors serving until the 2028 annual meeting.
  • Stockholders ratified the appointment of Manohar Chowdhry & Associates as the independent registered public accounting firm for the 2026 fiscal year.
  • The board was granted authority to issue 5,000,000 shares of common stock to employees, advisors, directors, and consultants based on performance, vesting, or incentive metrics.
  • The company amended its Articles of Incorporation to increase the authorized number of common stock shares from 150,000,000 to 600,000,000.
  • IGC Pharma is a clinical-stage biotechnology firm using AI to develop treatments for Alzheimer's disease, with its lead asset IGC-AD1 currently in a Phase 2 trial for agitation in Alzheimer's dementia.